©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2014; 20(43): 16029-16036
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16029
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16029
CYP2C19 polymorphism influences Helicobacter pylori eradication
Chao-Hung Kuo, Chien-Yu Lu, Hsiang-Yao Shih, Chung-Jung Liu, Meng-Chieh Wu, Huang-Ming Hu, Wen-Hung Hsu, Fang-Jung Yu, Deng-Chyang Wu, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
Chao-Hung Kuo, Chien-Yu Lu, Huang-Ming Hu, Wen-Hung Hsu, Fang-Jung Yu, Deng-Chyang Wu, Department of Medicine, Faculty of Medicine, College of Medicine and Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan
Hsiang-Yao Shih, Meng-Chieh Wu, Deng-Chyang Wu, Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung 812, Taiwan
Fu-Chen Kuo, Graduate Institute of Public Health, Kaohsiung Medical University, Kaohsiung 807, Taiwan
Fu-Chen Kuo, School of Medicine, College of Medicine, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan
Author contributions: Kuo CH wrote this manuscript; Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH and Yu FJ designed research; Wu DC and Kuo FC polished the paper.
Supported by Kaohsiung Medical University “Aim for the Top Universities Grant, grant No. KMU-TP103G01 and No. KMU-TP103 G04 (partially)
Correspondence to: Fu-Chen Kuo, PhD, School of Medicine, College of Medicine, E-Da Hospital, I-Shou University, No.1, Yida Rd., Yanchao Shiang, Kaohsiung 824, Taiwan. fuchenkuotw@yahoo.com.tw
Telephone: +886-7-73135612 Fax: +886-7-73135612
Received: February 21, 2014
Revised: July 4, 2014
Accepted: August 13, 2014
Published online: November 21, 2014
Processing time: 272 Days and 2.5 Hours
Revised: July 4, 2014
Accepted: August 13, 2014
Published online: November 21, 2014
Processing time: 272 Days and 2.5 Hours
Core Tip
Core tip: This manuscript outlines the impact of cytochrome P450 2C19 (CYP2C19) polymorphism on eradication of Helicobacter pylori (H. pylori), including the influences on first line triple therapies, rescue therapies and levofloxacin- based therapies. We suggest that the strategy of eradicating H. pylori should include the examination of CYP2C19 polymorphism, especially for patients receiving rescue therapies or with drug resistances.